This memo is to inform you that the Medical Genetics Laboratories will discontinue the JAK2 R683 Mutation Analysis test effective February 20, 2014. We will continue to offer an extensive menu of cancer genetic tests including JAK2 V617F (Test Code 9010) and JAK2 Exon 12 (Test Code 9015) mutation analyses. We also offer a Myeloproliferative Neoplasia Panel that includes JAK2 V617F, JAK2 Exon 12, and MPL Exon 10 mutation analyses (Test Code 9050).
Test Discontinuation Memorandum
Baylor Genetics
Baylor Genetics is a joint venture of H.U. Group Holdings and the #1 NIH-funded genetics program at Baylor College of Medicine. A pioneer of precision medicine for nearly 40 years, Baylor Genetics now offers a full spectrum of clinically relevant genetic testing, access to world-renowned experts, and the confidence to provide patients with the best care. Baylor Genetics, located in Houston’s Texas Medical Center, serves clients in 50 states and 16 countries.